Glucose-regulated protein 78 and platelet deposition: effect of rosuvastatin

Blanca Molins1, Esther Peña, Teresa Padro

  • 1Cardiovascular Research Center, Consejo Superior de Investigaciones Científicas- Institut Català de Ciències Cardiovasculars, Hospital de Santa Creu i Sant Pau (Universitat Autonoma de Barcelona), Barcelona, Spain.

Insights

Rosuvastatin reduces platelet deposition by inhibiting 78-kDa glucose-regulated protein (GRP78) translocation. This study reveals GRP78

Area of Science:

  • Cardiovascular Biology
  • Platelet Physiology
  • Pharmacology

Background:

  • Platelet-vessel wall interactions and thrombosis are critical in cardiovascular disease.
  • Understanding the molecular mechanisms of platelet activation under shear stress is essential.

Purpose of the Study:

  • To investigate the effect of rosuvastatin on platelet deposition under controlled shear conditions.
  • To identify novel platelet proteins involved in shear-induced platelet activation.

Main Methods:

  • Blood perfusion over type I collagen at varying shear rates.
  • Confocal microscopy for measuring platelet deposition.
  • Two-dimensional gel electrophoresis to analyze platelet subproteome.

Main Results:

  • Rosuvastatin significantly reduced platelet deposition.
  • Identified 18 differentially expressed proteins, including increased surface 78-kDa glucose-regulated protein (GRP78).
  • Blockade of platelet GRP78 increased deposition and tissue factor procoagulant activity.

Conclusions:

  • Rosuvastatin inhibits platelet deposition by modulating GRP78 translocation.
  • This study establishes a novel functional role for GRP78 in platelet activation beyond its chaperone function.
Abstract